Biogen to consolidate operations in MIT’s first Kendall Common building
New global headquarters will further solidify the company’s pioneering role in the Kendall Square innovation ecosystem.
Toward video generative models of the molecular world
Starting with a single frame in a simulation, a new system uses generative AI to emulate the dynamics of molecules, connecting static molecular structures and developing blurry pictures into videos.
MIT researchers introduce Boltz-1, a fully open-source model for predicting biomolecular structures
With models like AlphaFold3 limited to academic research, the team built an equivalent alternative, to encourage innovation more broadly.
Noninvasive imaging method can penetrate deeper into living tissue
Using high-powered lasers, this new method could help biologists study the body’s immune responses and develop new medicines.
Cellular traffic congestion in chronic diseases suggests new therapeutic targets
Chronic diseases like diabetes are prevalent, costly, and challenging to treat. A common denominator driving them may be a promising new therapeutic target.
A new framework to efficiently screen drugs
Novel method to scale phenotypic drug screening drastically reduces the number of input samples, costs, and labor required to execute a screen.
MIT chemists synthesize plant-derived molecules that hold potential as pharmaceuticals
Large multi-ring-containing molecules known as oligocyclotryptamines have never been produced in the lab until now.
MIT engineers find a way to protect microbes from extreme conditions
By helping microbes withstand industrial processing, the method could make it easier to harness the benefits of microorganisms used as medicines and in agriculture.
Creating the crossroads
Through academia and industry, Gevorg Grigoryan PhD ’07 says there is no right path — just the path that works for you.
CHARMed collaboration creates a potent therapy candidate for fatal prion diseases
A new gene-silencing tool shows promise as a future therapy against prion diseases and paves the way for new approaches to treating disease.
MIT-Takeda Program wraps up with 16 publications, a patent, and nearly two dozen projects completed
The program focused on AI in health care, drawing on Takeda’s R&D experience in drug development and MIT’s deep expertise in AI.
A smarter way to streamline drug discovery
The SPARROW algorithm automatically identifies the best molecules to test as potential new medicines, given the vast number of factors affecting each choice.
Scientists identify mechanism behind drug resistance in malaria parasite
SMART researchers find a cellular process called transfer ribonucleic acid (tRNA) modification influences the malaria parasite’s ability to develop resistance.
Taking RNAi from interesting science to impactful new treatments
Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, has turned the promise of RNAi research into a new class of powerful therapies.
Improving drug development with a vast map of the immune system
Immunai’s founders were researchers at MIT when they launched their company to help predict how patients will respond to new treatments.